glp-1 pipeline Drug 2026 Emerging Trends in the Development

In a phase 3 trial (REDEFINE-2) of adults with T2DM and a BMI of 27 kg/m 2 and above, combining the GLP-1 receptor agonist semaglutide with the long-acting amylin analogue cagrilintide resulted in greater weight loss than placebo at 68 weeks (13.7% vs 3.4%)

From Gold Rush To Guardrails: The Dark Side Of The GLP-1 Boom The GLP-1 economy has become a gold rushthousands of telehealth startups competing to fill prescriptions as fast as possible

Overeating can lead to weight gain if the person consumes more calories than they burn off

The other 2 noncode amino acids affect the pharmacokinetic profile, optimal GIP activity, and glucagon levels [86]

If you are curious about how semaglutide compares to other compounds sometimes discussed in similar regulatory contexts, the breakdown of semaglutide vs tirzepatide is worth reading